Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage

被引:21
|
作者
Li, Zhi [1 ]
Rotival, Maxime [2 ]
Patin, Etienne [2 ]
Michel, Frederique [1 ]
Pellegrini, Sandra [1 ]
机构
[1] Inst Pasteur, Unit Cytokine Signaling, INSERM, U1221, Paris, France
[2] Inst Pasteur, Unit Human Evolutionary Genet, CNRS, UMR2000, Paris, France
来源
PLOS ONE | 2020年 / 15卷 / 01期
关键词
GENETIC ASSOCIATION; INTERFERON; EXPRESSION; RECEPTOR; POLYMORPHISMS; SUSCEPTIBILITY; MUTATIONS; CHINESE; QUANTIFICATION; RESISTANCE;
D O I
10.1371/journal.pone.0225289
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
TYK2 belongs to the JAK protein tyrosine kinase family and mediates signaling of numerous antiviral and immunoregulatory cytokines (type I and type III IFNs, IL-10, IL-12, IL-22, IL-23) in immune and non-immune cells. After many years of genetic association studies, TYK2 is recognized as a susceptibility gene for some inflammatory and autoimmune diseases (AID). Seven TYK2 variants have been associated with AIDs in Europeans, and establishing their causality remains challenging. Previous work showed that a protective variant (P1104A) is hypomorphic and also a risk allele for mycobacterial infection. Here, we have studied two AID-associated common TYK2 variants: rs12720270 located in intron 7 and rs2304256, a non-synonymous variant in exon 8 that causes a valine to phenylalanine substitution (c.1084 G > T, Val362Phe). We found that this amino acid substitution does not alter TYK2 expression, catalytic activity or ability to relay signaling in EBV-B cell lines or in reconstituted TYK2-null cells. Based on in silico predictions that these variants may impact splicing of exon 8, we: i) analyzed TYK2 transcripts in genotyped EBV-B cells and in CRISPR/Cas9edited cells, ii) measured splicing using minigene assays, and iii) performed eQTL (expression quantitative trait locus) analysis of TYK2 transcripts in primary monocytes and whole blood cells. Our results reveal that the two variants promote the inclusion of exon 8, which, we demonstrate, is essential for TYK2 binding to cognate receptors. In addition and in line with GTEx (Genetic Tissue Expression) data, our eQTL results show that rs2304256 mildly enhances TYK2 expression in whole blood. In all, these findings suggest that these TYK2 variants are not neutral but instead have a potential impact in AID.
引用
收藏
页数:20
相关论文
共 50 条
  • [1] Two Rare Disease-Associated Tyk2 Variants Are Catalytically Impaired but Signaling Competent
    Li, Zhi
    Gakovic, Milica
    Ragimbeau, Josiane
    Eloranta, Maija-Leena
    Ronnblom, Lars
    Michel, Frederique
    Pellegrini, Sandra
    JOURNAL OF IMMUNOLOGY, 2013, 190 (05): : 2335 - 2344
  • [2] Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator
    Molitor, Tyler
    Hayashi, Genki
    Lin, Mei-Yao
    Dunn, Carissa
    Peterson, Nathan
    Poston, Robert
    Kurnellas, Michael
    Traver, David
    Patel, Seona
    Akgungor, Zeynep
    Leonardi, Virginia
    Lewis, Colizel
    Segales, Joshua
    Wood, Steve
    Rassoulpour, Arash
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 611 - 611
  • [3] Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors
    Du, Si-Shi
    Fang, Yu-Qing
    Zhang, Wen
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2900 - 2920
  • [4] TYK2 in Tumor Immunosurveillance
    Karjalainen, Anzhelika
    Shoebridge, Stephen
    Krunic, Milica
    Simonovic, Natalija
    Tebb, Graham
    Macho-Maschler, Sabine
    Strobl, Birgit
    Mueller, Mathias
    CANCERS, 2020, 12 (01)
  • [5] Functional analyses of three human TYK2 variants
    Ragimbeau, Josiane
    Gakovic, Milica
    Eloranta, Maija L.
    Pellegrini, Sandra
    CYTOKINE, 2008, 43 (03) : 241 - 241
  • [6] In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
    Prchal-Murphy, Michaela
    Witalisz-Siepracka, Agnieszka
    Bednarik, Karoline T.
    Putz, Eva Maria
    Gotthardt, Dagmar
    Meissl, Katrin
    Sexl, Veronika
    Mueller, Mathias
    Strobl, Birgit
    ONCOIMMUNOLOGY, 2015, 4 (11):
  • [7] Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor
    Kato, Jun-Ya
    Korenaga, Shigeru
    Iwakura, Masaru
    SSRN, 2022,
  • [8] Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
    Liu, Chunjian
    Lin, James
    Langevine, Charles
    Smith, Daniel
    Li, Jianqing
    Tokarski, John S.
    Khan, Javed
    Ruzanov, Max
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Gillooly, Kathleen M.
    Shuster, David
    Zhang, Yifan
    Thankappan, Anil
    McIntyre, Kim W.
    Chaudhry, Charu
    Elzinga, Paul A.
    Chiney, Manoj
    Chimalakonda, Anjaneya
    Lombardo, Louis J.
    Macor, John E.
    Carter, Percy H.
    Burke, James R.
    Weinstein, David S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) : 677 - 694
  • [9] The role of Tyk2 in adaptive immunity
    Simma, O
    Sexl, V
    Stoiber, D
    PHARMACOLOGY, 2005, 75 (04) : 199 - 199
  • [10] Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
    Kato, Jun-ya
    Korenaga, Shigeru
    Iwakura, Masaru
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79